Bay Street News

Syneos Health Releases the 2019 Health Trend Ten, Outlining Critical Shifts Impacting Drug Development and Commercialization

eBook Provides Biopharma Decision Makers With What’s-Next Insights to Navigate Challenges and Capitalize on the Opportunities Ahead

RALEIGH, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) — Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released a trends forecast outlining critical shifts and the underlying dynamics that will shape biopharmaceutical decision making in 2019. The Health Trend Ten looks beyond numbers and statistics, turning industry uncertainties into informative trends, relevant questions and actionable insights.

“In 2019, healthcare marketplace dynamics will demand heightened agility and responsiveness when it comes to biopharmaceutical decision making,” said Alistair Macdonald, Chief Executive Officer of Syneos Health. “Data alone won’t be enough to solve today’s and tomorrow’s complex problems. Data will need to be synthesized to deliver decision-driving insights and targeted solutions that deliver on the possibilities of science.”

Syneos Health harnessed the knowledge and experience of the Company’s industry-leading subject matter experts across the clinical and commercial spectrum to generate 10-macro trends and 40 themes for 2019. Top trends include:

Author of the eBook Leigh Householder, Executive Vice President, Insights and Innovation at Syneos Health commented, “We enter this new year inspired by the power of science, the persistence of patients and the success of survivors. These trends – and the important conversation they fuel – will drive biopharmaceutical leaders to innovate how they test and commercialize therapies for patients.”

This is the eighth year Syneos Health is issuing a healthcare trend forecast that assembles and analyzes clues, examples, and actionable insights collected by the Company’s global trend watchers. Building off the success of the Company’s Communications and Commercial trends forecasts issued in previous years, this year’s edition is the first of its kind – providing end-to-end biopharmaceutical industry perspectives.

Trends Implications – Connect with Us to Learn More

About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 23,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

Contacts
Investor Relations:
Ronnie Speight
Senior Vice President, Investor Relations
+1 919 745 2745
investor.relations@syneoshealth.com

Press/Media:
Danielle DeForge
Executive Director, External Communications
+1 202 210 5992
danielle.deforge@syneoshealth.com